OM Pharma marketed portfolio includes products for respiratory tract infections, lower urinary tract infections, chronic venous insufficiency, microangiopathies (e.g. diabetic retinopathy), haemorrhoids and menometrorrhagia (heavy menstrual bleeding).

Its key brands are Broncho-Vaxom, Dicynone, Doxium and Uro-Vaxom. Broncho-Vaxom and Uro-Vaxom benefit from an increasing medical interest as international health authorities and governments address the ongoing rise of antimicrobial resistance worldwide due to an overuse of antibiotics, in particular for respiratory infections. Broncho-Vaxom plays an important role as it is indicated to prevent recurrent respiratory infections of both viral and bacterial etiology. Many antibiotics used for the treatment of urinary tract infections are becoming less and less effective as resistance to these drugs grows. Every infection Uro-Vaxom can reduce contributes therefore to the reduction of overall antibiotic consumption. More information can be found under “Therapeutic areas” and “Products”.

OM Pharma has a well-diversified country base spanning both developed and Emerging Markets thanks to a tight network of partners.

Dicynone - Etamsylate